Adverse Effects of Amiodarone: Pathogenesis, Incidence and Management

Gerald Naccarelli, Robert L. Rinkenberger, Anne H. Dougherty, David M. Fitzgerald

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Amiodarone is an extremely effective antiarrhythmic agent for the treatment of both life-threatening ventricular arrhythmias and refractory supraventricular tachyarrhythmias. Subjective minor side effects are common with amiodarone but rarely require discontinuation of therapy and are often handled by dose reduction. Serious end-organ toxicity, including pulmonry fibrosis and drug-induced hepatitis, have been the most common indications for discontinuing amiodarone therapy in these patients.

Original languageEnglish (US)
Pages (from-to)246-253
Number of pages8
JournalMedical Toxicology and Adverse Drug Experience
Volume4
Issue number4
DOIs
StatePublished - Jan 1 1989

Fingerprint

Amiodarone
Incidence
Chemical and Drug Induced Liver Injury
Tachycardia
Refractory materials
Toxicity
Cardiac Arrhythmias
Fibrosis
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Toxicology

Cite this

Naccarelli, Gerald ; Rinkenberger, Robert L. ; Dougherty, Anne H. ; Fitzgerald, David M. / Adverse Effects of Amiodarone : Pathogenesis, Incidence and Management. In: Medical Toxicology and Adverse Drug Experience. 1989 ; Vol. 4, No. 4. pp. 246-253.
@article{d8e875f82f664edb8b3942541a344afe,
title = "Adverse Effects of Amiodarone: Pathogenesis, Incidence and Management",
abstract = "Amiodarone is an extremely effective antiarrhythmic agent for the treatment of both life-threatening ventricular arrhythmias and refractory supraventricular tachyarrhythmias. Subjective minor side effects are common with amiodarone but rarely require discontinuation of therapy and are often handled by dose reduction. Serious end-organ toxicity, including pulmonry fibrosis and drug-induced hepatitis, have been the most common indications for discontinuing amiodarone therapy in these patients.",
author = "Gerald Naccarelli and Rinkenberger, {Robert L.} and Dougherty, {Anne H.} and Fitzgerald, {David M.}",
year = "1989",
month = "1",
day = "1",
doi = "10.1007/BF03259911",
language = "English (US)",
volume = "4",
pages = "246--253",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "4",

}

Adverse Effects of Amiodarone : Pathogenesis, Incidence and Management. / Naccarelli, Gerald; Rinkenberger, Robert L.; Dougherty, Anne H.; Fitzgerald, David M.

In: Medical Toxicology and Adverse Drug Experience, Vol. 4, No. 4, 01.01.1989, p. 246-253.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Adverse Effects of Amiodarone

T2 - Pathogenesis, Incidence and Management

AU - Naccarelli, Gerald

AU - Rinkenberger, Robert L.

AU - Dougherty, Anne H.

AU - Fitzgerald, David M.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Amiodarone is an extremely effective antiarrhythmic agent for the treatment of both life-threatening ventricular arrhythmias and refractory supraventricular tachyarrhythmias. Subjective minor side effects are common with amiodarone but rarely require discontinuation of therapy and are often handled by dose reduction. Serious end-organ toxicity, including pulmonry fibrosis and drug-induced hepatitis, have been the most common indications for discontinuing amiodarone therapy in these patients.

AB - Amiodarone is an extremely effective antiarrhythmic agent for the treatment of both life-threatening ventricular arrhythmias and refractory supraventricular tachyarrhythmias. Subjective minor side effects are common with amiodarone but rarely require discontinuation of therapy and are often handled by dose reduction. Serious end-organ toxicity, including pulmonry fibrosis and drug-induced hepatitis, have been the most common indications for discontinuing amiodarone therapy in these patients.

UR - http://www.scopus.com/inward/record.url?scp=0024349440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024349440&partnerID=8YFLogxK

U2 - 10.1007/BF03259911

DO - 10.1007/BF03259911

M3 - Review article

C2 - 2671595

AN - SCOPUS:0024349440

VL - 4

SP - 246

EP - 253

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 4

ER -